Increasing costs, loss of drug exclusivity and crowded drug classes have prompted the need for better outcomes data to ensure optimization of payer resources
Manufacturers are still behind the eight ball in understanding what payers need in terms of information, both clinical and economic data, said Nathan White, director, NucleusX Market Access, a medical communications company and Katya Svoboda, a partner with Percipient LLC, a strategic consulting firm in pharmaceuticals and biotech.
White and Svoboda explored what U.S. drug manufacturers need to do to catch up to their global counterparts in sharing the economic value of new products in AMCP Session 207.
“Manufacturers are mostly focused on product development, safety, clinical efficacy and regulatory approval, but now payers are demanding more data to effectively assess drug costs and outcomes,” White said.
NucleusX Market Access and Percipient conducted research based on interviews with 20 pharmacy and medical directors from U.S. payers, both national and regional as well as four payers across Europe and Australia, and manufacturers involved in market access or health outcomes.
The discussion covered:
• Ways to identify the evidence payers seek when a new product is launched;
• How payers are applying data and will in the next three to five years;
• Limitations of current evidence and opportunities for improvement and what types of data are most useful to payers.
Svoboda said that increasing costs, loss of drug exclusivity, growth in technology and crowded drug classes have prompted the need for better outcomes data to ensure optimization of resources.
“Outcomes data can help payers make more informed decisions to increase quality and lower costs,” she said.
Despite indicating a desire for such data, payers are skeptical about the credibility of clinical outcomes and peer-reviewed articles on new drugs from manufacturers when they suspect the literature might be biased. While payers want head-to-head studies of products, what they often have available are placebo-controlled trials.
"There are gaps," said Svoboda."Payers question manufacturer data credibility for a variety of reasons."
One reason why data is questioned is because negative results are often not published. She also said that in today's healthcare environment, payers are increasing their expectations for transparency.
The research the speakers presented indicates that payers are asking that study results be more applicable and actionable, illustrate credible and objective endpoints and demonstrate cost savings. However, payers also want more intelligence applicable to their member populations.
U.S. payers will use more outcomes data as accountable care organizations assume more risk and payers are required to demonstrate “rational” management decisions.
“The United States is five years behind Europe and Australia in setting requirements for presenting health economic data and outcomes,” said White. “These other countries have already established a collaborative, transparent process for disseminating information, while providing an opportunity for dialogue prior to a clinical development program.
Unlike many European countries, the United States does not have a single entity responsible for reviewing outcomes data, but AHRQ, PCORI and AMCP can provide resouces, according to the presenters.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More